Journal of Pharmaceutical Care 2016. 4(1-2):14-20.

Evaluation of Risk Factors for Hepatic Complications after Allogeneic Hematopoietic Stem Cell Transplantation
Zahrasadat Mirmoezi, Molouk Hadjibabaie, Ava Mansouri, Hamidreza Taghvaye Masoumi, Zahra Jahangard-Rafsanjani, Hossein Kamranzadeh


Background:  Hepatic dysfunction in patients who have undergone allogeneic haematopoietic stem cell transplantation (HSCT) is a major cause of morbidity and mortality. The aim of this study is to evaluate the incidence of post-transplantation hepatic complications in these patients.

Methods: A total of 121 patients (age above 15 with no abnormality in their hepatic tests) participated in the study. The influence of a variety of risk factors on the incidence, type, and pattern of hepatic dysfunction as well as the length of hospital stay related to these complications were studied.

Results:  As a whole, 76 patients (62%)—44 males and 32 females—were diagnosed with hepatic dysfunction after transplantation. As many as 31(25%) of the patients showed increased measures in their hepatic enzyme, while 45(37%) of them ended up with both abnormal enzyme measure and clinical symptoms including diarrhoea, skin rash, jaundice, and anorexia. The hepatic dysfunction rates owing to drug toxicity and GVHD (21.5% and 16.5%, respectively) proved to be the highest in our study. Analysing risk factors, the immunosuppressive regimen could affect the type of hepatic dysfunction—i.e., less patients with GVHD were found in the group who received ATG in their regimen (p-value =0.034).

Conclusion: According to these findings, the immunosuppressive regimen can play a role in preventing the incidence of GVHD. Less occurrence of hepatic complications, especially GVHD, may lead to less clinical symptoms and time of hospital stay.


hepatotoxicity; HSCT; risk factors

Full Text:



Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015;21(11):1863-9.

Jaing TH. Complications of haematopoietic stem cell transplantation. ISBT Science Series 2011;6(2):332-6.

Idilman R, Arat M. Hepatic complications of allogeneic hematopoietic cell transplantation/Allojeneik hematopoetik hucre naklinin hepatik komplikasyonlari. Turk J Hematol 2008;25(3):111-24.

Campo LD, León NG, Palacios DC, Lagana C, Tagarro D. Abdominal complications following hematopoietic stem cell transplantation. Radiographics 2014;34(2):396-412.

Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007;7(5):340-52.

Iqbal N, Salzman D, Lazenby AJ, Wilcox CM. Diagnosis of gastrointestinal graft-versus-host disease. Am J Gastroenterol 2000;95(11):3034-8.

Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997;97(4):855-64.

Holtan SG, Pasquini M, Weisdorf DJ. Acute graft-versus-host disease: a bench-to-bedside update. Blood 2014;124(3):363-73.

Arai S, Lee LA, Vogelsang GB. A systematic approach to hepatic complications in hematopoietic stem cell transplantation. J Hematother Stem Cell Res 2002 ;11(2):215-29.

Kim BK, Chung KW, Sun HS, et al. Liver disease during the first post- transplant year in bone marrow transplantation recipients: retrospective study. Bone Marrow Transplant 2000 ;26(2):193.

Özdogan O, Ratip S, Al Ahdab Y, et al. Causes and risk factors for liver injury following bone marrow transplantation. J Clin Gastroenterol 2003;36(5):421-6.

Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA2016;315(8):801-10.

Coppell JA, Richardson PG, Soiffer R, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant 2010;16(2):157-68.

Ruutu T, Van Biezen A, Hertenstein B, et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012;47(11):1459-64.

Kumar A, Mhaskar AR, Reljic T, et al. Antithymocyte globulin for acute- graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia2012;26(4):582-8.

Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 2003;54(1):29-52.

Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic stem- cell transplantation in AML and MDS using myeloablative versus reduced- intensity conditioning: the role of dose intensity. Leukemia 2006;20(2):322-8.

Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004;103(1):78-84.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.